Analytical Data
-
Gene name
OPRD1
- Application
-
Alternative Names
(D-OR-1)(DOR-1)
-
Species
Human
-
Source
E. coli
-
Tag
N- His
-
Purity
Greater than 90% as determined by SDS-PAGE.
-
Uniprot
P41143
-
Expression Region
1-372aa
-
Molecular Weight
41.9 kDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
OPRD1, also known as the delta-opioid receptor (DOR), is a vital member of the opioid receptor family, which plays a crucial role in modulating pain, mood, and stress responses in the central nervous system. The study of OPRD1 recombination proteins has garnered significant interest due to their potential therapeutic implications in treating various conditions, including chronic pain, depression, and addiction. The delta-opioid receptor exhibits a unique pharmacological profile distinct from the mu-opioid receptor, leading to a lower risk of addiction while still providing analgesic effects. Research has focused on elucidating the molecular mechanisms underlying OPRD1 signaling, receptor dimerization, and interactions with other cellular proteins. Recombinant OPRD1 proteins are instrumental in assessing drug efficacy and specificity, as well as in understanding receptor dynamics in neuronal models. Furthermore, advancements in biotechnology enable the characterization of OPRD1 variants, offering insights into individual differences in drug response and susceptibility to opioid-related disorders. As the opioid crisis emphasizes the need for safer pain management alternatives, OPRD1 represents a promising target for the development of novel therapeutics. Ongoing studies aim to optimize OPRD1-based drugs that exploit its analgesic properties while minimizing side effects, ultimately contributing to more effective and responsible pain management strategies.
